Europe Life Sciences Weekly Signal #61: Four Pharma Results, One Budgeting Question

Week of 26 October–1 November 2026 · Evidence checked on 1 November · 5-minute read

This week’s Q3 disclosures show why European commercial plans need separate investment cases for launches, expansion and mature franchises.

The useful European growth story this week sits below the regional headline. A region can grow while an established franchise contracts, or look flat while an important launch gains traction. A single growth target hides those different investment needs.

Between 27 and 30 October, Novartis, GSK, AstraZeneca and Sanofi published third-quarter results. Their reported European growth ranged from −0.9% to +12% at constant exchange rates. The more useful question for a 2027 plan is what sits inside each regional result.

Year-on-year growth at constant exchange rates, using each company’s own Europe segment. AstraZeneca reports total revenue; the others report sales or turnover. Country exposure, portfolios and reporting definitions differ. This is a comparison of reported growth, not a like-for-like ranking of commercial performance. Sources are linked in the company names.

Read the portfolio before judging the region

GSK’s European growth of 3% combines specialty medicines up 9% and general medicines down 3% in the quarter. Those businesses require different investment decisions, even inside the same regional plan.

Novartis reports a similar tension: Kisqali, Kesimpta, Leqvio and Scemblix drove European growth, partly offset by competition affecting Promacta and Xolair. The regional total compresses expansion and erosion into one number.

At Sanofi, European Dupixent sales rose 16.1% in Q3 while Lovenox fell 17.8%. The company attributes the region’s overall decline to influenza vaccines and legacy medicines. It also says its global influenza/COVID-19 vaccine decline mainly reflects seasonal deliveries shifting towards Q4.

That timing matters. A weak quarter should not automatically become a structural budget cut. Sanofi’s European sales were still up 1.9% over the first nine months.

AstraZeneca’s nine-month European figures illustrate another complication: Imfinzi grew 31%, with momentum from new indications, while Soliris fell 47%. The report describes both conversion from Soliris to Ultomiris and biosimilar pressure. Some product decline therefore reflects a transition within the company’s own franchise.

These disclosures support examining the portfolio. They do not isolate how much of the cross-company growth gap comes from product mix, access, pricing, shipment timing or execution. Nor do regional sales reveal how individual affiliates are staffed or funded.

Give released resources an investment destination

AstraZeneca’s new Reshaping for Sustainable Growth programme makes the allocation question explicit. It expects up to $2 billion in one-time restructuring costs and $1.5 billion in annualised pre-tax run-rate benefits, with activities essentially complete by end-2029. Savings would be reinvested principally in the pipeline.

This is a group-level plan with projected benefits. It does not specify European affiliate budgets. It does, however, state what the resources released are intended to fund. A country investment case needs equivalent clarity about its destination and expected return.

Fund three commercial jobs with different measures

For a 2027 European plan, I would separate three funding decisions at the level of medicine, indication and country. Product age alone is a poor dividing line: an established medicine can have a new indication or a newly reimbursed market.

Establish access and launch. Fund the work needed to turn an approval into an accessible treatment. Track reimbursement milestones, treatment-centre readiness and uptake in the defined eligible population. State which access or capacity constraints must change before spending increases.

Expand an established opportunity. Fund additional reach or uptake where the incremental contribution justifies the investment. Specify the patient group, market and evidence behind the opportunity, and the result that would justify further funding.

Sustain a mature franchise. Manage cash contribution, tender performance and supply reliability. Make the choice to retain, partner or transfer explicit. Where patients are moving to a successor product, assess the economics across the franchise before treating the older product’s decline as a commercial failure.

These are distinct investment cases, not instructions to build three separate teams. Shared medical, data and commercial capabilities can serve all three; their costs and priorities should remain visible.

If a productivity initiative releases time or budget, name the opportunity receiving it. Avoid counting the same hours as both a cost reduction and capacity for additional work. The plan should show what changes in delivery as well as what changes in expenditure.

Before signing off the 2027 plan, ask: can each material spending change be traced to a named portfolio opportunity and a measurable outcome?

Analysis of company disclosures published 27–30 October 2026. Commercial planning recommendations are the author’s interpretation. Views are personal.